FendX Technologies (FendX), a nanotechnology company developing surface protection coatings, announces that it has entered into a Collaborative Research Agreement (CRA) on December 1, 2023, with McMaster University (McMaster) which details the research and development plan to create a protective catheter coating using FendX’s nanotechnology licensed pursuant to the license agreement.
In the first and second year, maximum research funding to McMaster will be $150,547 each year.
Reduce Catheter Blockage Rates Using Nanotechnology
"
We are excited about the prospect of developing a coating for catheters using our nanotechnology which we believe will reduce catheter blockage caused by either blood clots or bacterial biofilms,” said Dr. Carolyn Myers, president and chief executive officer of FendX.
“
Early work conducted at McMaster has demonstrated significant reduction in the adherence of both bacteria and blood which could potentially translate to reduced bacterial biofilm or blood clot formation. Our aim is to further this research to tackle the medical need to reduce catheter blockage rates, which can be costly and interfere with patient therapy,” continued Dr. Myers.
“
We anticipate the development of this coating formulation will also strengthen our overall intellectual property portfolio," added Dr. Myers.
The CRA outlines more fully the research and development work to be conducted by McMaster on behalf of FendX as well as a payment schedule for the maximum research funding requirements. The term of the CRA is for 24 months commencing on the effective date of December 1, 2023, unless terminated in accordance with the provisions of the CRA.
Source: FendX Technologies